Drug Study Pantoprazole Sodium (Antiulcer) PDF

Preview

Summary

DRUG STUDY FOR PANTOPRAZOLEClassification Indications Dosage Mechanism of Action Side Effects / Adverse Effect Nursing Responsibilities PANTOPRAZOLE SODIUMTherapeutic class: Antiulcer DrugsPharmacologic class: PPIs or Proton- pump inhibitorsMaintenance of healing of erosive esophagitisAdults: 40 mg ...

Description

DRUG STUDY FOR PANTOPRAZOLE Classification PANTOPRAZOLE SODIUM

Indications Maintenance of healing of erosive esophagitis

Dosage Adults: 40 mg PO once daily.

Therapeutic class: Antiulcer Drugs

Short-term treatment of erosive esophagitis associated with GERD

Adults: 40 mg PO once daily for up to 8 weeks. For patients who haven't healed after 8 weeks of treatment, another 8-week course may be considered. Or, 40 mg IV once daily for 7 to 10 days. Switch to PO form as soon as patient is able to take orally.

Pharmacologic class: PPIs or Protonpump inhibitors

Children age 5 and older weighing 40 kg or more: 40 mg PO once daily for up to 8 weeks. Children age 5 and older weighing 15 to less than 40 kg: 20 mg PO once daily for up to 8 weeks.

Long-term maintenance of healing erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in patients with GERD

Adjust-a-dose: Consider dosage reduction in children who are poor CYP2C19 metabolizers (enzyme protein) Adults: 40 mg PO once daily

Mechanism of Action Inhibits proton pump activity by binding to hydrogen-potassium adenosine triphosphatase, located at secretory surface of gastric parietal cells, to suppress gastric acid secretion.

Side Effects / Adverse Effect CNS: • Anxiety • Asthenia • Dizziness • Headache • Insomnia • Migraine • Pain • Depression • Vertigo

Route: PO Onset: Unknown Peak: 2 ½ hours Duration: >24 hours IV Onset: 15-30 min Peak: Unknown Duration: 24 hours

EENT: • Blurred vision • Rhinitis

Half-life: 1 hour

CV: • Chest pain

• Edema • Pharyngitis • Sinusitis

GI: • Abdominal pain • Diarrhea • Eructation • Gastroenteritis • Nausea GU: • Urinary frequency

• Constipation • • • •

Dyspepsia Flatulence GI disorder Vomiting

• UTI

HEMATOLOGIC: • Leukopenia • thrombocytopenia HEPATIC: • Elevated liver enzyme levels METABOLIC: • Hyperglycemia

• Hyperlipidemia

MUSCULOSKELETAL:

Nursing Responsibilities • Prolonged use of PPIs may cause low magnesium levels. Monitor magnesium levels before start of treatment and periodically thereafter. • Monitor patient for signs and symptoms of low magnesium level, such as abnormal HR or rhythm, palpitations, muscle spasms, tremor, or seizures. In children, abnormal HR may present as fatigue, upset stomach, dizziness, and light-headedness. Magnesium supplementation or drug discontinuation may be required. • May increase risk of CDAD. Evaluate for CDAD in patients who develop diarrhea that doesn't improve. • Instruct patient to take exactly as prescribed and at about the same time every day. • Advise patient that drug can be taken without regard to meals. • Tell patient to swallow tablet whole with 1 glass of water and not to crush, split, or chew it. • Tell patient that antacids don't affect drug absorption. • Teach patient to report all adverse reactions and to recognize and report signs and symptoms of low magnesium levels. • Instruct the patient that drug appears in human milk. Patient

Treatment of pathologic hypersecretion caused by Zollinger-Ellison syndrome

Dyspepsia

Adults: Individualize dosage. • Usual dosage is 40 mg PO b.i.d. • Usual IV dose is 80 mg IV every 12 hours for no more than 6 days. • For those needing a higher dose, 80 mg every 8 hours is expected to maintain acid output below 10 mEq/hour. • Maximum daily dose is 240 mg/day. • When converting from IV to PO form, ensure continuity of suppression of acid secretion. Adults: 20 to 40 mg once daily for 4 weeks.

Reference: Lippincott, W. W. (2021). Nursing 2021 Drug Handbook (41st Edition). Wolters Kluwer.

• Arthralgia • Hypertonia

• Back pain • Neck pain

RESPIRATORY: • Bronchitis • Increase cough

• Dyspnea • URI

SKIN: • Rash • Urticaria

• Pruritus

OTHER: • Flulike syndrome • Injection site reaction

• Infection • Photosensitivity reactions

should discontinue breastfeeding or discontinue drug....